MBX Biosciences, Inc.

MBX

MBX Biosciences, Inc.

MBX

Insider Sentiment (TTM):

Last Purchase:2026-03-13Last Sale:2026-05-08Shares Purchased (TTM):725,166Shares Sold (TTM):70,841

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:51,310,620Shares Outstanding:46,576,204Institutional Ownership Pct.:110.16%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Series A Convertible Preferred Stock	-	-	-	-	-	-	0	4
Assets
Series B Convertible Preferred Stock	-	-	-	-	-	-	0	11
Assets Current
Cash And Cash Equivalents At Carrying Value	54	45	75	223	40	30	49	133
Marketable Securities Current	364	395	298	169	185	211	213	144
Prepaid Expense And Other Assets Current	9	9	8	6	4	3	5	4
Assets Current	428	449	382	398	229	244	267	281
Property Plant And Equipment Net	5	3	3	2	2	2	1	1
Operating Lease Right Of Use Asset	3	0	0	1	1	0	0	0
Other Assets Noncurrent	1	1	0	0	0	0	0	0
Assets	436	453	385	400	232	246	269	282
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	4	7	3	4	6	4	5	5
Accrued Liabilities Current	19	7	12	8	6	6	6	6
Operating Lease Liability Current	1	0	0	0	0	0	0	0
Liabilities Current	24	15	15	12	12	10	11	11
Operating Lease Liability Noncurrent	3	0	0	0	1	-	0	0
Liabilities	26	15	16	13	12	11	11	11
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	-
Redeemable Noncontrolling Interest Equity Preferre…	-	-	-	-	-	-	0	0
Common Stock Value	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	696	686	593	590	400	397	395	393
Retained Earnings Accumulated Deficit	-285	-248	-224	-202	-181	-161	-138	-122
Accumulated Other Comprehensive Income Loss Net Of…	-1	-1	0	0	0	0	0	0
Stockholders Equity	410	438	369	388	219	235	257	271
Liabilities And Stockholders Equity	436	453	385	400	232	246	269	282
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0
Temporary Equity Shares Authorized	-	-	-	-	-	-	-	0
Temporary Equity Shares Issued	-	-	-	-	-	-	-	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	500	500	500	500	500	500	500	500
Common Stock Shares Issued	48	48	45	45	34	33	33	33
Shares Outstanding	48	48	45	45	34	33	33	33
Temporary Equity Shares Outstanding	-	0	0	0	0	0	-	0

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-9.33%	50.71%	78.62%	-	-	-	-	-	-	-	-	-
2025	2.06%	11.94%	23.43%	35.58%	57.32%	52.74%	39.41%	24.90%	52.99%	18.03%	6.55%	12.59%
2024	-	-	-	-	-	-	-12.40%	-13.57%	-53.70%	-16.27%	25.54%	28.47%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Liquidity Ratios
Current Ratio	18.08	30.79	24.62	32.95	19.50	23.31	24.19	25.75
Quick Ratio	17.69	30.20	24.12	32.47	19.13	22.97	23.72	25.37
Working Capital	404.20M	433.97M	366.04M	385.44M	217.43M	233.80M	256.24M	270.25M
Leverage & Debt
Debt to Equity	0.06	0.03	0.04	0.03	0.06	0.04	0.04	0.04
Debt Ratio	0.06	0.03	0.04	0.03	0.05	0.04	0.04	0.04
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	-	-	-
Per Share Metrics
Diluted EPS TTM	-2.19	-1.86	-2.38	-3.18	-3.15	-	-	-
Free Cash Flow Per Share TTM	-1.83	-1.71	-2.24	-1.64	-2.20	-	-	-
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	-	-	-
Growth Metrics
Net Income Growth (1Y)	-0.88%	-	-	-	-	-	-	-
EPS Growth (1Y)	-30.49%	-	-	-	-	-	-	-
Valuation Metrics
P/E TTM	-25.24	-16.05	-13.24	-5.51	-3.63	-	-	-
P/B TTM	6.43	3.18	3.12	1.54	1.74	1.05	0.76	0.62
Market Cap	2.63B	1.39B	1.15B	598.48M	381.62M	246.58M	196.15M	169.28M
Enterprise Value	2.58B	1.35B	1.08B	375.35M	341.84M	216.68M	146.80M	36.41M
Calculated Values
Free Cash Flow TTM	-87.26M	-79.82M	-81.88M	-56.21M	-73.70M	-	-	-
Net Debt	-54.12M	-45.21M	-75.29M	-223.13M	-39.78M	-29.90M	-49.35M	-132.87M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-05-08Sale

Owner: Azoulay, Salomon

Title: Chief Medical Officer

Shares: 70,003

Price/Share: $38.34

Value: $2,683,915.02

Shares Owned: 14,769

Relationship: Officer

Ownership: Direct

2026-05-06Sale

Owner: Azoulay, Salomon

Title: Chief Medical Officer

Shares: 231

Price/Share: $29.54

Value: $6,823.74

Shares Owned: 14,769

Relationship: Officer

Ownership: Direct

2026-05-06Sale

Owner: Hawryluk, P. Kent

Title: President & CEO

Shares: 607

Price/Share: $29.54

Value: $17,930.78

Shares Owned: 727,667

Relationship: Director,Officer

Ownership: Direct

2026-03-13Purchase

Owner: Hawryluk, P. Kent

Title: President & CEO

Shares: 18,500

Price/Share: $28.41

Value: $525,585.00

Shares Owned: 486,777

Relationship: Director,Officer

Ownership: Indirect

2025-10-20Purchase

Owner: Hawryluk, P. Kent

Title: President & CEO

Shares: 20,000

Price/Share: $13.64

Value: $272,800.00

Shares Owned: 468,277

Relationship: Director,Officer

Ownership: Indirect

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-05-08	Azoulay, Salomon	Officer	Chief Medical Officer	Direct	Sale	70,003	38.34	$2,683,915.02	14,769	4
2026-05-06	Azoulay, Salomon	Officer	Chief Medical Officer	Direct	Sale	231	29.54	$6,823.74	14,769	4
2026-05-06	Hawryluk, P. Kent	Director,Officer	President & CEO	Direct	Sale	607	29.54	$17,930.78	727,667	4
2026-03-13	Hawryluk, P. Kent	Director,Officer	President & CEO	Indirect	Purchase	18,500	28.41	$525,585.00	486,777	4
2025-10-20	Hawryluk, P. Kent	Director,Officer	President & CEO	Indirect	Purchase	20,000	13.64	$272,800.00	468,277	4
2025-10-17	Hoerter, Steven L.	Director	-	Indirect	Purchase	20,000	13.25	$265,000.00	20,000	4
2025-09-26	Fhmls, X, L.P., Topper Ja…	TenPercentOwner	-	Indirect	Purchase	666,666	18.00	$11,999,988.00	5,219,440	4
2025-04-08	Pescovitz, Ora H.	Director	-	Direct	Purchase	7,693	5.89	$45,311.77	24,329	4
2025-02-18	Gordon, Carl L	Director,TenPercentOwner	-	Indirect	Purchase	143,170	10.84	$1,551,962.80	3,255,000	4
2025-02-18	Orbimed, Genesis Gp Llc, …	Director,TenPercentOwner	-	Indirect	Purchase	143,170	10.84	$1,551,962.80	3,255,000	4
2025-02-04	Hawryluk, P. Kent	Director,Officer	President & CEO	Indirect	Purchase	50,000	10.69	$534,500.00	448,277	4
2024-09-16	Chang, Carmen	TenPercentOwner	-	Indirect	Purchase	500,000	16.00	$8,000,000.00	3,614,486	4
2024-09-16	Fhmls, X, L.P., Fhmls X, …	TenPercentOwner	-	Direct	Purchase	625,000	16.00	$10,000,000.00	4,552,774	4
2024-09-16	Baskett, Forest	TenPercentOwner	-	Indirect	Purchase	500,000	16.00	$8,000,000.00	3,614,486	4
2024-09-16	Florence, Anthony A. Jr.	TenPercentOwner	-	Indirect	Purchase	500,000	16.00	$8,000,000.00	3,614,486	4
2024-09-16	Aynechi, Tiba	Director	-	Indirect	Purchase	750,000	16.00	$12,000,000.00	2,136,335	4
2024-09-16	Gordon, Carl L	Director,TenPercentOwner	-	Indirect	Purchase	750,000	16.00	$12,000,000.00	3,158,428	4
2024-09-16	Mathers, Edward T	Director,TenPercentOwner	-	Indirect	Purchase	500,000	16.00	$8,000,000.00	3,614,486	4
2024-09-16	Yang, Rick	TenPercentOwner	-	Indirect	Purchase	500,000	16.00	$8,000,000.00	3,614,486	4
2024-09-16	Orbimed, Advisors Llc, Or…	Director,TenPercentOwner	-	Indirect	Purchase	750,000	16.00	$12,000,000.00	3,158,428	4
2024-09-16	Nea, Partners 17, L.P., N…	TenPercentOwner	-	Direct	Purchase	500,000	16.00	$8,000,000.00	3,614,486	4
2024-09-16	Makhzoumi, Mohamad	TenPercentOwner	-	Indirect	Purchase	500,000	16.00	$8,000,000.00	3,614,486	4
2024-09-16	Walker, Paul Edward	TenPercentOwner	-	Indirect	Purchase	500,000	16.00	$8,000,000.00	3,614,486	4
2024-09-16	Sandell, Scott D	TenPercentOwner	-	Indirect	Purchase	500,000	16.00	$8,000,000.00	3,614,486	4
2024-09-16	Behbahani, Ali	TenPercentOwner	-	Indirect	Purchase	500,000	16.00	$8,000,000.00	3,614,486	4
2024-09-16	Heron, Patrick J	Director,TenPercentOwner	-	Indirect	Purchase	625,000	16.00	$10,000,000.00	4,552,774	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

110.16%

Inst. Shares: 51,310,620

Shares Outstanding: 46,576,204

2025-12-31

130.15%

Inst. Shares: 47,511,915

Shares Outstanding: 36,506,092

2025-09-30

136.93%

Inst. Shares: 46,827,872

Shares Outstanding: 34,198,597

2025-06-30

105.93%

Inst. Shares: 35,428,429

Shares Outstanding: 33,446,385

2025-03-31

103.37%

Inst. Shares: 34,537,589

Shares Outstanding: 33,412,386

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	51,310,620	46,576,204	110.16%
2025-12-31	47,511,915	36,506,092	130.15%
2025-09-30	46,827,872	34,198,597	136.93%
2025-06-30	35,428,429	33,446,385	105.93%
2025-03-31	34,537,589	33,412,386	103.37%
2024-12-31	31,734,768	10,642,954	298.18%
2024-09-30	29,024,016	6,515,616	-
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

MBX Biosciences, Inc. (MBX) — SEC Financial Statements & Analysis

MBX Biosciences, Inc. (MBX) is a pharmaceutical preparations company, incorporated in DE. MBX Biosciences, Inc. trades on Nasdaq as: MBX. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), MBX Biosciences, Inc. reported a Debt-to-Equity ratio of 0.06x, a Price-to-Book (P/B) ratio of 6.43x (TTM), at a market cap of $2.63B. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 0.06x
P/B TTM: 6.43x
Market Cap: $2.63B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is MBX Biosciences, Inc. in?

MBX Biosciences, Inc. (MBX) operates in the Pharmaceutical Preparations industry.

What is MBX's market cap?

MBX Biosciences, Inc. (MBX) has a market capitalization of $2.63B as of 2026-06-30.

What exchange does MBX trade on?

MBX Biosciences, Inc. (MBX) trades on the Nasdaq.

Where is MBX Biosciences, Inc. incorporated?

MBX Biosciences, Inc. is incorporated in DE.